Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.74% ILS1.360
America/New_York / 6 sep 2023 @ 15:59
FUNDAMENTALS | |
---|---|
MarketCap: | 4.97 mill |
EPS: | -2.35 |
P/E: | -0.579 |
Earnings Date: | Nov 29, 2023 |
SharesOutstanding: | 3.65 mill |
Avg Daily Volume: | 0.0389 mill |
RATING 2023-10-03 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Neutral | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
Revenue | n/a | n/a | n/a | n/a | ||
Gr.Profit | n/a | n/a | n/a | n/a | ||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.579 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.10x |
Company: PE -0.579 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
ILS 0.745 - 0.855 ( +/- 6.88%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-01-01 | Margolin Yael | Sell | 133 200 | Restricted Share Units |
2023-01-01 | Margolin Yael | Sell | 0 | Ordinary Shares |
2023-01-01 | Laster Morris C | Sell | 133 200 | Restricted Share Units |
2023-01-01 | Laster Morris C | Sell | 0 | Ordinary Shares |
2023-01-01 | Lowell George | Sell | 133 200 | Restricted Share Units |
INSIDER POWER |
---|
-100.00 |
Last 23 transactions |
Buy: 0 | Sell: 12 745 600 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | ILS1.360 (0.74% ) |
Volume | 0.0227 mill |
Avg. Vol. | 0.0389 mill |
% of Avg. Vol | 58.21 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.